Core Capital Management & Research, inc.’s Pacific Biosciences PACB Stock Holding History

Core Capital Management & Research, inc.’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$699	Buy	+518	New	+$753	﹤0.01%	201

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Core Capital Management & Research, inc.'s PACB Position: Q2 2026 in Review

Core Capital Management & Research, inc. opened a new position in Pacific Biosciences (PACB) in Q2 2026: 518 shares worth $699. The stake represents ﹤0.01% of the portfolio and ranks #201 among its holdings.

223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Core Capital Management & Research, inc. held 518 shares of Pacific Biosciences worth $699 as of Q2 2026.
Pacific Biosciences was a new Core Capital Management & Research, inc. position in Q2 2026.
Pacific Biosciences made up ﹤0.01% of Core Capital Management & Research, inc.'s portfolio in Q2 2026, its #201 holding.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Core Capital Management & Research, inc.'s 13F filing for Q2 2026, filed 9 Sep 2026.